2023 World Conference on Lung Cancer (Posters)-EP12.01. A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib

EP12.01. A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib - PDF(Abstract)

Back to course

Pdf Summary

This case report discusses a 47-year-old male patient with non-small cell lung cancer (NSCLC) who had co-mutations of MET exon 14 skipping and EGFR exon 21 L858R. The patient initially presented with head discomfort and left lower limb weakness, which were determined to be due to brain metastases. The patient also had a soft tissue mass in the upper lobe of the right lung and mediastinal lymphadenopathy.<br /><br />The patient received bevacizumab combined with PC regimen to control central nervous system (CNS) symptoms before genetic testing results were available. After two cycles of treatment, the lung and intracranial masses showed a partial response. Genetic testing revealed the presence of both EGFR and MET mutations, for which there is currently a lack of effective treatment options.<br /><br />The patient was then given aumolertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) approved in China. The patient's lung and intracranial masses continued to narrow and maintain a partial response. Furthermore, the metastatic lesions in the left frontal lobe also shrank, and the enhancement lesion disappeared. The patient has achieved a progression-free survival (PFS) of more than 14 months with no significant drug-related adverse events.<br /><br />This case report is significant as it is the first to apply aumolertinib to NSCLC patients with EGFR and MET co-mutations. It provides valuable insights into the treatment of such patients. Currently, a phase Ib clinical trial is underway to evaluate aumolertinib combined with a c-MET inhibitor (HS-10241) for patients with advanced NSCLC. This trial may provide a promising treatment plan for NSCLC patients with similar mutations in the future.<br /><br />Overall, this case highlights the potential benefits of a targeted therapy approach for NSCLC patients with specific genetic mutations, such as EGFR exon 21 L858R and MET exon 14 skipping mutations.

Asset Subtitle

Yan Chen

Meta Tag

Speaker Yan Chen

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

case report

non-small cell lung cancer

NSCLC

MET exon 14 skipping

EGFR exon 21 L858R

brain metastases

genetic testing

bevacizumab

PC regimen

aumolertinib